In a stunning turn of events that exposes the hypocrisy and paralysis of GOP leadership, Democrat Rep. Ro Khanna (D-CA) has introduced legislation to codify President Donald Trump’s historic executive order slashing prescription drug prices—while Republican lawmakers in the House sit on their hands.
Yes, a Democrat is moving to advance one of the boldest America First policies ever issued on healthcare, while the Republican-controlled Congress fails to act.
Trump’s Game-Changing Order: The Most Favored Nation Policy
President Trump’s executive order, signed this week, implements the “Most Favored Nation” (MFN) pricing policy, which mandates that Americans will pay the same for prescription drugs as the lowest-paying nation on Earth. This would instantly lower U.S. drug prices by 30% to 80%, saving trillions in taxpayer money and putting an end to the global price-gouging that makes Americans foot the bill for Big Pharma’s profits.
Trump: “Our country will finally be treated fairly, and our citizens’ healthcare costs will be reduced by numbers never even thought of before.”
And now, Ro Khanna is doing what House GOP leaders refuse to do—turn that executive order into permanent law.
Khanna Calls Out Big Pharma’s Grip on Congress
In a rare moment of bipartisan clarity, Khanna posted on X:
“Will Congress members stand with $16 billion in Big Pharma money, or with the American people by co-sponsoring this bipartisan legislation?”
He’s right to ask. According to watchdogs, Congress has delivered fewer bills to President Trump than any Congress in 70 years, despite being under Republican control. And when it comes to battling Big Pharma, many Republicans have shown more loyalty to corporate donors than to American families.
Tillis and Thune: The New Faces of the Swamp
Adding insult to injury, Sen. Thom Tillis (R-NC) and Sen. John Thune (R-SD)—both prominent voices in the GOP—have signaled opposition to Trump’s MFN drug pricing order. During a recent Senate hearing on Pharmacy Benefit Managers, both senators parroted Big Pharma’s talking points, worrying more about “market disruption” than about the people paying $800 for the same insulin that costs $40 overseas.
If you’re looking for proof that D.C. is still infected with Swamp rot, look no further than Republicans fighting President Trump’s most popular and pro-consumer healthcare reform.
GOP Voters Want Action — Not Excuses
Polling consistently shows that prescription drug price reform is a top concern for working-class and senior voters—the very base that delivered Republicans the House. Trump’s MFN policy is a no-brainer win: it’s America First, it’s bipartisan, and it saves lives.
Yet Republican leadership is AWOL.
Where is the GOP House on this? Where is the courage to stand with President Trump, Ro Khanna, and millions of Americans being crushed by drug costs?
The Bottom Line: Republicans Must Lead or Step Aside
If Republican leaders refuse to seize this historic opportunity to slash prices and crush Big Pharma’s monopoly racket, they are handing Democrats the populist mantle on a silver platter.
Trump delivered the policy. Khanna delivered the bill. The only question now is:
Will the GOP deliver for the American people—or once again serve the donor class?